SOPHiA GENETICS (NASDAQ:SOPH) Research Coverage Started at Guggenheim

Guggenheim started coverage on shares of SOPHiA GENETICS (NASDAQ:SOPH) in a research report sent to investors on Thursday morning, Marketbeat Ratings reports. The firm issued a buy rating and a $6.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. BTIG Research increased their price objective on SOPHiA GENETICS from $7.00 to $8.00 and gave the company a buy rating in a report on Wednesday, March 6th. Royal Bank of Canada restated an outperform rating and set a $8.00 target price on shares of SOPHiA GENETICS in a research report on Wednesday, March 6th.

SOPHiA GENETICS Stock Performance

SOPH stock opened at $4.58 on Thursday. The company’s 50 day moving average price is $4.85 and its 200 day moving average price is $4.83. SOPHiA GENETICS has a fifty-two week low of $2.13 and a fifty-two week high of $7.37. The firm has a market capitalization of $299.44 million, a price-to-earnings ratio of -4.09 and a beta of 1.09.

SOPHiA GENETICS (NASDAQ:SOPH) last released its earnings results on Tuesday, May 7th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.04. SOPHiA GENETICS had a negative net margin of 113.71% and a negative return on equity of 47.56%. The firm had revenue of $15.78 million for the quarter, compared to analyst estimates of $16.80 million. Equities analysts forecast that SOPHiA GENETICS will post -1.04 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in SOPHiA GENETICS by 90.0% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 13,834 shares of the company’s stock valued at $65,000 after purchasing an additional 6,552 shares during the last quarter. Legato Capital Management LLC purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at about $235,000. Essex Investment Management Co. LLC purchased a new stake in SOPHiA GENETICS in the 4th quarter valued at about $584,000. Federated Hermes Inc. grew its holdings in SOPHiA GENETICS by 100.0% in the 3rd quarter. Federated Hermes Inc. now owns 160,000 shares of the company’s stock valued at $408,000 after buying an additional 80,000 shares during the period. Finally, Moloney Securities Asset Management LLC grew its holdings in SOPHiA GENETICS by 111.4% in the 1st quarter. Moloney Securities Asset Management LLC now owns 178,000 shares of the company’s stock valued at $878,000 after buying an additional 93,800 shares during the period. Institutional investors and hedge funds own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharmaceutical companies through its own sales force as well as distributors and industry collaborators in Switzerland, France, Italy, rest of Europe, North America, the United States, Latin America, and the Asia-pacific.